Canakinumab

drugbox-mab


source = Human
target = IL-1β
CAS_number =
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Intravenous, subcutaneous

Canakinumab (INN, codenamed ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It is being developed by Novartis for the treatment of rheumatoid arthritis. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease [cite journal | title = Therapies for COPD | author = Yasothan U, Kar S | year = 2008 | journal = Nat Rev Drug Discov | url = http://npg.nature.com/nrd/journal/vaop/ncurrent/pdf/nrd2533.pdf | doi = 10.1038/nrd2533 | volume = 7 | pages = 285 | format = dead link|date=June 2008 – ^{[http://scholar.google.co.uk/scholar?hl=en&lr=&q=author%3A+intitle%3ATherapies+for+COPD&as_publication=Nat+Rev+Drug+Discov&as_ylo=2008&as_yhi=2008&btnG=Search Scholar search]} ] and in phase III studies for Muckle-Wells syndrome, a rare genetic disease. [cite web | url = http://www.clinicaltrials.gov/ct2/show/NCT00465985 | title = Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome | date = January 8 2008 | publisher = U.S. National Institutes of Health | work = ClinicalTrials.gov | accessdate = 2008-03-26] [cite journal | title = Muckle-Wells syndrome | author = Ferrer E, Moral MA, Bozzo J | year = 2007 | journal = Drugs Fut | volume = 32 | issue = 19 | pages = 919 | doi = 10.1358/dof.2007.032.10.1143492]

References